Introduction: Although PNH is primarily recognized as a hematologic disorder, its clinical manifestations often extend beyond the bone marrow 1,2. Unlike typical thrombotic conditions, PNH is characterized by a high risk of thrombosis in atypical sites, including the portal, mesenteric, and hepatic veins 1-3. These thrombotic events may result in h

BETTER-CARE Primary Results in Individualized Breast Cancer Follow-Up At ASCO 2026, Achim Wöckel, MD, of University Hospital Würzburg, Germany, presented primary results from the BETTER-CARE trial of assessing an individualized survivorship care model after primary breast cancer. Transforming Post-Treatment Care in Breast Cancer: Follow-up care aft

ctDNA Surveillance in Early Breast Cancer: Handling Requests and Results At ASCO 2026, Erin Frances Cobain, MD, Michigan Medicine, discusses challenges in ctDNA surveillance, focusing on results and managing patient requests in early breast cancer care. Translating ctDNA Detection into Improved Outcomes: ctDNA detection in early-stage breast cancer

IRIS-A: Phase II Trial in Stage IA HER2-Positive Breast Cancer At ASCO 2026, Ruoxi Wang, MD, PhD, of Fudan University Shanghai Cancer Center, presented IRIS-A findings on adjuvant capecitabine plus trastuzumab in stage IA HER2-positive breast cancer. Five-Year Outcomes with Capecitabine and Trastuzumab: Adjuvant treatment for small, node-negative H

Leveraging Artificial Intelligence in Oncology Care and Research: From Proof of Concept to Adoption At ASCO 2026, Julian Hong, MD, MS, FAMIA, University of California, San Francisco, highlighted the key steps needed to translate AI innovations into meaningful clinical impact in oncology. Translating AI into Clinical Oncology Practice: AI has evolve

Strategic Integration of ADCs With Targeted Therapies Presented by Paolo Tarantino, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA at the 2026 Annual ASCO Meeting Combination therapy can have two possible rationales in oncology- combinations with non-overlapping MoA to address all baseline clones, or therapy aimed at preventing/de

ASCO 2026 Highlights: De Novo HER2-Positive Metastatic Breast Cancer—Cure or Control? This session was led by Eric P. Winer, MD (Yale Cancer Center), Philip Poortmans, MD (Iridium Network), Miriam Mutebi, MD (Aga Khan University), and Amy Sanders Clark, MD, MSCE (Abramson Cancer Center, University of Pennsylvania), who explored the evolving managem

Aging Phenotypes and Cancer Related Cognitive Impairment Presented by Yin Ting Cheung, PhD, Associate Professor and Associate Director (Research), School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, reported evidence from pediatric cancer survivors linking aging phenotypes with cancer-related cognitive impai

Evolving Paradigms in Breast Cancer Presented by Alice Y. Ho, MD, Houston Methodist Academic Institute, delivered primary results from TBCRC‑053 (P‑RAD), a randomized trial of varying preoperative radiation doses with pembrolizumab and chemotherapy in node‑positive breast cancer. Emerging Chemoimmunotherapy Strategies in Breast Cancer Emerging stra